Literature DB >> 28668389

Inducible liver-specific overexpression of gankyrin in zebrafish results in spontaneous intrahepatic cholangiocarcinoma and hepatocellular carcinoma formation.

Shin-Jie Huang1, Chih-Lun Cheng2, Jim-Ray Chen3, Hong-Yi Gong4, Wangta Liu5, Jen-Leih Wu6.   

Abstract

Liver cancer is the second leading cause of death worldwide. As such, establishing animal models of the disease is important for both basic and translational studies that move toward developing new therapies. Gankyrin is a critical oncoprotein in the genetic control of liver pathology. In order to evaluate the oncogenic role of gankyrin without cancer cell inoculation and drug treatment, we overexpressed gankyrin under the control of the fabp10a promoter. A Tet-Off system was used to drive expression in hepatocytes. At seven to twelve months of age, gankyrin transgenic fish spontaneously incurred persistent hepatocyte damage, steatosis, cholestasis, cholangitis, fibrosis and hepatic tumors. The tumors were both hepatocellular carcinoma (HCC) and intrahepatic cholangiocarcinoma (ICC). ICC is the second most frequent primary liver cancer in human patients and the first to develop in this tumor model. We further investigated the role of complement C3, a central molecule of the complement system, and found the expression levels of both in mRNA and protein are decreased during tumorigenesis. Together, these findings suggest that gankyrin can promote malignant transformation of liver cells in the context of persistent liver injury. This transformation may be related to compensatory proliferation and the inflammatory microenvironment. The observed decrease in complement C3 may allow transforming cells to escape coordinated induction of the immune response. Herein, we demonstrate an excellent zebrafish model for liver cancers that will be useful for studying the molecular mechanisms of tumorgenesis.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Complement C3; Gankyrin; Hepatocellular carcinoma; Intrahepatic cholangiocarcinoma; Zebrafish

Mesh:

Substances:

Year:  2017        PMID: 28668389     DOI: 10.1016/j.bbrc.2017.06.164

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  6 in total

1.  Small-Molecule Gankyrin Inhibition as a Therapeutic Strategy for Breast and Lung Cancer.

Authors:  Dipti Kanabar; Mimansa Goyal; Emma I Kane; Tejashri Chavan; Abbas Kabir; Xuechun Wang; Snehal Shukla; Joseph Almasri; Sona Goswami; Gizem Osman; Marino Kokolis; Donald E Spratt; Vivek Gupta; Aaron Muth
Journal:  J Med Chem       Date:  2022-06-27       Impact factor: 8.039

2.  Cooperation between liver-specific mutations of pten and tp53 genetically induces hepatocarcinogenesis in zebrafish.

Authors:  Juanjuan Luo; Chunjiao Lu; Meilan Feng; Lu Dai; Maya Wang; Yang Qiu; Huilu Zheng; Yao Liu; Li Li; Bo Tang; Chuan Xu; Yajun Wang; Xiaojun Yang
Journal:  J Exp Clin Cancer Res       Date:  2021-08-20

3.  PARP1 activation increases expression of modified tumor suppressors and pathways underlying development of aggressive hepatoblastoma.

Authors:  Leila Valanejad; Ashley Cast; Mary Wright; Karl-Dimiter Bissig; Rebekah Karns; Matthew T Weirauch; Nikolai Timchenko
Journal:  Commun Biol       Date:  2018-06-11

4.  DnaJ-PKAc fusion induces liver inflammation in a zebrafish model of fibrolamellar carcinoma.

Authors:  Sofia de Oliveira; Ruth A Houseright; Benjamin G Korte; Anna Huttenlocher
Journal:  Dis Model Mech       Date:  2020-04-30       Impact factor: 5.758

5.  Small Molecule Cjoc42 Improves Chemo-Sensitivity and Increases Levels of Tumor Suppressor Proteins in Hepatoblastoma Cells and in Mice by Inhibiting Oncogene Gankyrin.

Authors:  Amber M D'Souza; Ashley Cast; Meenasri Kumbaji; Maria Rivas; Ruhi Gulati; Michael Johnston; David Smithrud; James Geller; Nikolai Timchenko
Journal:  Front Pharmacol       Date:  2021-03-04       Impact factor: 5.988

6.  Liver Proliferation Is an Essential Driver of Fibrosis in Mouse Models of Nonalcoholic Fatty Liver Disease.

Authors:  Ashley Cast; Meenasri Kumbaji; Amber D'Souza; Katherine Rodriguez; Anita Gupta; Rebekah Karns; Lubov Timchenko; Nikolai Timchenko
Journal:  Hepatol Commun       Date:  2019-07-17
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.